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Dexmedetomidine is a selective a2 adrenergic agonist. Although dexmedetomidine is widely used for
sedation and analgesia, it frequently produces hypotension and bradycardia. The present study aimed to
evaluate the effects of dexmedetomidine on cardiac function and coronary circulation using Langendorff-
perfused guinea pig hearts. Coronary perfusion pressure (CPP) and left ventricular pressure (LVP) were
continuously monitored, and electric ﬁeld stimulation (EFS) was applied to stimulate sympathetic nerve
terminals. Dexmedetomidine almost completely inhibited the EFS-induced increase in LVP at all ages.
The effect of dexmedetomidine on coronary artery resistance varied according to postnatal age, i.e.,
dexmedetomidine had little effect on CPP in young hearts (<4 weeks) but increased CPP by 10 mmHg at 4
e8 weeks and by 15 mmHg at >8 weeks. The increase in CPP in adult hearts was inhibited by imiloxan,
an a2B antagonist, and prazosin, an a1 antagonist. The results suggest that dexmedetomidine acts on a2
adrenergic receptors at sympathetic nerve terminals to suppress the release of norepinephrine. In
addition, the ﬁndings suggest that dexmedetomidine directly affects a1 adrenoceptors and/or a2B
adrenoceptors on coronary smooth muscles to increase CPP. The age-related changes in a adrenoceptor
subtypes may be linked to the cardiodepressant effects of dexmedetomidine.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Dexmedetomidine is a selective and speciﬁc agonist for pre- and
post-synaptic a2 adrenergic receptors, and is widely used, not only
as an adjunct to anesthesia, but also as a sedative during me-
chanical ventilation in the intensive care unit (1e4). Although
adverse effects, such as bradycardia and hypotension, are observed
in up to 30% of patients, they are generally easily managed with
intravenous ﬂuids and atropine (2). In rare cases, however, dex-
medetomidine causes profound left ventricular dysfunction and
refractory shock (5e8). Tanaka et al. (9) reported that
dexmedetomidine-related severe cardiovascular cases could be
divided into two groups, i.e., fatal cardiovascular collapse preceded
by hypotension, and severe bradycardia resulting in asystole with
no other signs of circulatory depression immediately before the
event. Multiple factors that can affect cardiac function and: þ81 18 836 2604.
rmacological Society.
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d/4.0/).hemodynamics seem to be involved in these clinical cases. For
example, patients in intensive care units have likely received
sedative drugs such as propofol, fentanyl, and other anesthetics
besides dexmedetomidine, and patient background characteristics,
such as cardiovascular disease or disease severity, are not identical.
Therefore, it is difﬁcult to deﬁnitively state that dexmedetomidine
is the cause of cardiac arrest (9). Animal studies have also shown
dexmedetomidine-related cardiovascular effects, but the results
are not always consistent among various studies. Lin et al (10) re-
ported vasopressor effects and a decrease in heart rate and cardiac
output induced by dexmedetomidine during propofol or isoﬂurane
anesthesia, but they were within clinically acceptable ranges.
Augmented bradycardia and a decrease in cardiac output have been
reported in the presence of fentanyl (11) or isoﬂurane (12). Pascoe
(12) reported that a high dose of dexmedetomidine (3 mg/kg) pro-
duced signiﬁcant increases in systemic arterial pressure, central
venous pressure, and pulmonary occlusion pressure, accompanied
by decreases in heart rate, cardiac output, and oxygen delivery in
the presence of isoﬂurane.
Three subtypes of a2 adrenergic receptors have been identiﬁed
(a2A/D, a2B, and a2C) on the basis of pharmacological analysis andnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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different tissues and organs, and they mediate many different
physiological and pharmacological effects in the cardiovascular
system, including both vascular constriction and dilatation (13,14).
Although dexmedetomidine possesses a high speciﬁcity for the a2
versus the a1 receptor, it does not show signiﬁcant differences in
afﬁnity for the three adrenoceptor subtypes (13). It is thus possible
that dexmedetomidine mediates both sympatholytic and vaso-
constrictive hemodynamic effects (1,15,16). Recent studies have
suggested that clinically relevant genetic polymorphisms, as well as
patient traits/characteristics and pharmacokinetics in critically ill
patients, could affect the response to dexmedetomidine (17,18).
In addition to the above receptor-mediated actions, it has also
been reported that dexmedetomidine has direct effects on various
ion channels, such as vascular KATP channels, hyperpolarization-
activated cation currents, and the neuronal delayed-rectiﬁer Kþ
current and Naþ current (19e22). All these pharmacological actions
should be examined to clarify the mechanisms underlying the se-
vere adverse effects of dexmedetomidine observed in human and
animal studies.
In the present study, we aimed to evaluate the effects of dex-
medetomidine on cardiac parameters, using Langendorff-perfused
hearts of guinea pigs of various ages. We found that the effect of
dexmedetomidine on coronary artery resistance varied according
to postnatal age.
2. Materials and methods
2.1. Measurement of left ventricular pressure and coronary
perfusion pressure
All animal experiments were approved by The Animal Ethics
Committee of Akita University School of Medicine. Left ventricular
pressure (LVP) and coronary perfusion pressure (CPP) were
measured using the previously reported method (23). In brief,
guinea pigs were anesthetized with pentobarbital (50 mg/kg, i.p.),
and the heart was rapidly excised and ascending aorta cannulated
through the aorta. The excised heart was then mounted on a Lan-
gendorff perfusion device (Fig. 1A), and was continuously perfused
with oxygenated Tyrode solution containing 5.5 mM atropine
(37 C). The ﬂow rate of the perfusate was adjusted to obtain a
perfusion pressure of approximately 50 mmHg, and kept constant
throughout the experiment. The ﬂow rate was maintained at
6e12 mL/min in the present study. A ﬂuid-ﬁlled balloon was
inserted into the left ventricle via the left atrium, and the balloon
volume was adjusted to maintain the end-diastolic pressure at
10 mmHg. LVP and CPP were recorded using a PowerLab (AD In-
struments, Colorado Springs, CO, USA) at a sampling frequency of
1 kHz. Electroﬁeld stimulation (EFS) was applied via metal elec-
trodes placed at both sides of the heart in the chamber to stimulate
the sympathetic nerve terminals (Fig. 1). A train of four electrical
ﬁeld pulses of 1 ms duration with a 3 ms interval was repeated at
4 Hz, and usually 5 s stimulation was sufﬁcient to achieve a satu-
rated response to a given intensity of stimulation (24). Although the
EFS sometimes triggered ventricular extrasystole, it was only
transient and did not affect measurement of LVP and CPP during the
course of the study.
2.2. Isolation of ventricular myocytes and patch clamping
Ventricular myocytes were isolated from guinea pig hearts by
enzymatic dissociation as previously described (23). Brieﬂy, a
Langendorff perfusion system was used to perfuse the heart with
Ca2þ-free Tyrode solution for 5 min. Subsequently, the perfusate
was switched to Ca2þ-free Tyrode solution containing 0.02%collagenase (Wako, Osaka, Japan), and the heart was digested for
approximately 30 min. The heart was then rinsed with high Kþ/low
Cle solution before the left ventricle was dissected and stored in the
same solution at 4 C until required. A small piece of ventricular
tissue was dissected and gently agitated in the recording chamber
(0.5 mL volume) containing normal Tyrode solution. Once the cells
had settled on the base of the recording chamber, they were
perfused with normal Tyrode solution at 2e3 mL/min. All experi-
ments were performed at 36e37 C on rod-shaped quiescent single
cells that had clear sarcomere striations.
Cells were patch-clamped to record whole-cell currents using a
patch-clamp ampliﬁer (EPC-7; List, Darmstadt, Germany). Patch
pipettes were prepared from glass capillaries (Warner Instrument
Co., Hamden, CT, USA) using a micropipette puller (Model P-97;
Sutter Instrument Co., Novato, CA, USA). Electrode resistance
ranged from 3 to 5 MU. Data were recorded at 2e10 kHz on a
personal computer using pClamp software (Axon Instruments,
Foster City, CA, USA).
2.3. Solutions and drugs
Tyrode solution comprised (in mM): NaCl 136.9; KCl 5.4; CaCl2
1.8; MgCl2 0.53; NaH2PO4 0.33; 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 5.0; and glucose 5.5 (pH
7.4, adjusted with NaOH). The pipette solution for recording action
potentials contained (in mM): K-aspartate 110; KCl 20; Na2ATP 4;
MgCl2 2; HEPES 5; and EGTA 10 (pH 7.0, adjusted with KOH). The
high Kþ, low Cl solution for storage of the isolated cardiomyocytes
comprised 10 mM taurine, 10 mM oxalic acid, 70 mM L-glutamic
acid, 25 mMKCl, 10 mM KH2PO4, 0.5 mM EGTA,11 mM glucose, and
10 mM HEPES (pH 7.4, adjusted with KOH).
Dexmedetomidine, clonidine, yohimbine, and prazosin were
purchased from SigmaeAldrich (St. Louis, MO, USA).
2.4. Statistical analysis
The peak LVP, heart rate, CPP and coronary ﬂow were measured
and the differences between the presence and absence of dexme-
detomidine were calculated. Results are expressed as mean ± SEM.
Comparisons of more than three groups were conducted by one-
way repeated-measures analysis of variance with the TukeyeK-
ramer HSD test. Comparisons of two groups were conducted by a
paired t-test. A P-value < 0.05 was considered to indicate statistical
signiﬁcance. All statistical analyses were performed using JMP
software (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Effects of dexmedetomidine on CPP, LVP, and heart rate in hearts
of different ages
The excised heart was mounted on a Langendorff perfusion
device and was continuously perfused with oxygenated Tyrode
solution containing 5.5 mM atropine (37 C). The ﬂow rate of the
perfusate was adjusted to approximately 50 mmHg. After the CPP,
LVP, and heart rate had stabilized for more than 20 min, 10 nM and
100 nM dexmedetomidine were applied via the coronary arteries.
Fig. 2A shows representative recordings of CPP, LVP, dp/dt, and
heart rate of hearts of guinea pigs aged <4 weeks (left), 4e8 weeks
(middle) and >8 weeks (right). LVP, dp/dt, and heart rate were little
affected by dexmedetomidine in any age of heart examined, indi-
cating that dexmedetomidine had no direct effect on cardiac
contractility and sino-atrial node function. In contrast, the CPP
varied signiﬁcantly depending on age, i.e., dexmedetomidine had
little effect on CPP in young hearts while, at concentrations >10 nM,
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Fig. 1. Measurement of LVP, CPP and HR in isolated heart of guinea pigs. (A) An excised guinea pig heart was mounted on a Langendorff perfusion device. A ﬂuid-ﬁlled balloon
catheter connected to a pressure transducer was inserted into the left ventricle via the left atrium. The balloon volume was adjusted to maintain the end-diastolic pressure at
approximately 10 mmHg. The heart was continuously perfused with oxygenated Tyrode solution (37 C) at a constant ﬂow (6e8 mL/min) using a peristaltic pump. Representative
raw traces for LVP and CPP are shown at the right panel. (B) EFS was applied to stimulate the sympathetic nerve terminals (delay: 4 ms; duration: 1 ms for 5 s). LVP was increased by
EFS. LVP: Left ventricular pressure; CPP: Coronary perfusion pressure; HR: Heart rate; EFS: Electrical ﬁeld stimulation.
Fig. 2. Age-dependent effect of dexmedetomidine on CPP. (A) Representative traces showing the effects of dexmedetomidine on CPP and LVP in hearts of guinea pigs of various ages.
Left, < 4 weeks; middle, 4e8 weeks; right, >8 weeks. Note that dexmedetomidine markedly increased CPP at ages >4 weeks. (BeD) Age-dependent effects of dexmedetomidine on
peak LVP (B), HR (C) and CPP (D). *P < 0.05 (vs. age < 4 weeks); **P < 0.01 (vs. age < 4weeks).
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rate, and CPP are summarized in Fig. 2BeD. Therewas no signiﬁcant
difference in the peak LVP before and after addition of 10 or 100 nM
dexmedetomidine, while dexmedetomidine signiﬁcantly increased
CPP in older hearts (age <4 weeks vs. age 4e8 weeks: P < 0.05; age
<4 weeks vs. age >8 weeks: P < 0.01; Fig. 2D). We also examined
the effect of a non-selective a2 adrenoceptor agonist clonidine on
CPP at 4e8 weeks guinea pigs. The CPP was increased by
3.1 ± 1.4mmHg at 10 nM (p¼ 0.157), and 3.3 ± 1.9mmHg at 100 nM
clonidine (p ¼ 0.051), and these values were not statistically
signiﬁcant.
To conﬁrm that coronary vascular resistance is increased in
response to dexmedetomidine in older guinea pigs, dexmedeto-
midine was applied during constant CPP. In Fig. 3, CPP was main-
tained constant at 50 mmHg and the effects of dexmedetomidine
on coronary ﬂow and LVP were examined in hearts from guinea
pigs >8 weeks old. Coronary ﬂow was found to decrease in a
concentration-dependent manner. In contrast, the peak LVP was
little affected by dexmedetomidine (Fig. 3C).3.2. Mechanism of the response of coronary artery resistance to
dexmedetomidine
To investigate the mechanisms underlying the
dexmedetomidine-induced increase in coronary artery resistance
in adult guinea-pigs, effects of an a2B adrenoceptor inhibitor, imi-
loxan, were examined. Imiloxan (3 mM) suppressed the effect of
10 nMdexmedetomidine, but not that of 100 nM dexmedetomidine
(Fig. 4A). The effect of prazosin, a potent a1 antagonist, was also
investigated. Prazosin (1 mM) completely inhibited the increase in
CPP induced by 10 nM dexmedetomidine, and its effect was slightly
attenuated when the dexmedetomidine concentration was
increased to 100 nM.Fig. 3. Decrease in coronary ﬂow induced by dexmedetomidine in aged hearts. (A) Represen
CPP, dexmedetomidine was applied cumulatively to the perfusate in the heart of > 8-week-o
ﬂow (B) and peak LVP (C).3.3. Inhibitory effects of dexmedetomidine on LVP with EFS
In the experiment shown in Fig. 5A, a heart isolated from a
guinea pig >8 weeks old was mounted on a Langendorff apparatus
and was perfused with Tyrode solution. After the CPP, LVP, and
heart rate had stabilized for >20 min, 25V EFS was applied for 5 s,
resulting in a signiﬁcant increase in LVP accompanied by a biphasic
change in CPP, i.e., a transient increase was followed by sustained
decrease. Dexmedetomidine inhibited the EFS-induced changes in
LVP, and increased CPP in a concentration-dependent manner
(Fig. 5A). The inhibitory effect of dexmedetomidine on the EFS-
induced increase in LVP was also examined at various EFS ampli-
tudes (Fig. 5B). The relationship between the concentration of
dexmedetomidine and the increase in LVP showed a half-maximal
concentration at approximately 0.2 nM (Fig. 5C). Similar results
were observed in hearts isolated from guinea pigs <4 weeks and
4e8 weeks old (data not illustrated).
3.4. Effects of dexmedetomidine on the action potential of
ventricular myocytes
Effects of dexmedetomidine on the action potentials of isolated
ventricular myocytes were examined. Action potentials were eli-
cited every 10 s under conventional whole-cell clamp conditions,
and 100 nM dexmedetomidine was applied (Fig. 6). Dexmedeto-
midine had no effect on action potential duration or amplitude, or
on the resting potential. Similar results were obtained in three
other ventricular cells.
4. Discussion
The present study demonstrated that dexmedetomidine by it-
self had little effect on heart rate and on the dp/dt of the LVP, buttative traces showing the effects of dexmedetomidine on coronary ﬂow. Under constant
ld guinea pigs. (B, C) Concentration-dependent effect of dexmedetomidine on coronary
Fig. 4. Effects of imiloxan (A) and prazosin (B) on the dexmedetomidine-induced increase in CPP. Both imiloxan (3 mM) and prazosin (1 mM) suppressed the increase in CPP induced
by dexmedetomidine.
M. Hongo et al. / Journal of Pharmacological Sciences 131 (2016) 118e125122inhibited the EFS-induced increase in dp/dt of the LVP. Also, the
effect of dexmedetomidine on CPP differed depending on postnatal
age, i.e., it had little effect on CPP in young hearts (<4 weeks) but
increased CPP by 10 mmHg in 4e8-week-old hearts and by
15 mmHg in > 8-week-old hearts. This is the ﬁrst study toFig. 5. Effects of dexmedetomidine on the EFS-induced increase in LVP. (A) Representative tr
isolated heart from a > 8-week-old guinea pig. The arrows indicate the times of EFS. Note th
concentration dependent manner. (B) The increase in LVP under various concentrations of de
of dexmedetomidine on the EFS-induced increase in LVP.demonstrate an age-dependent effect of dexmedetomidine on
coronary vascular resistance.
There are three subtypes of a2 adrenoceptor, namely a2A/D, a2B,
and a2C (13,14). Most of the classical functions mediated by a2
adrenergic receptors, such as hypotension, sedation, analgesia,aces showing CPP and LVP in response to EFS, and the effect of dexmedetomidine in an
at dexmedetomidine inhibited the EFS-induced increase in LVP and increased CPP in a
xmedetomidine was plotted against EFS amplitude. (C) Concentration-dependent effect
Fig. 6. Action potentials were elicited every 10 s using conventional whole-cell clamp conditions, with representative traces illustrated. Dexmedetomidine had no effect on action
potential duration or amplitude, or on the resting potential (n ¼ 4).
M. Hongo et al. / Journal of Pharmacological Sciences 131 (2016) 118e125 123hypothermia, and anesthetic-sparing effect, are mediated primarily
by the a2A/D subtype. The a2B subtype is the principal mediator of
the hypertensive response to a2 agonists. The a2C subtype is
involved in many central nervous system processes such as the
startle reﬂex, the stress response, and locomotion. The three re-
ceptors bind most a2 adrenergic drugs, including dexmedetomi-
dine with similar afﬁnities, but with different efﬁcacies. It was
reported that dexmedetomidine was a full agonist at the a2B sub-
type and a partial agonist at the a2C subtype and the a2A/D subtype
(25).
In the present study, dexmedetomidine almost completely
inhibited the increase in LVP induced by EFS from hearts of guinea
pigs of all ages. This is consistent with the previous ﬁndings that the
a2A/D and a2C subtypes are important in the presynaptic inhibition
of norepinephrine release (26), and that a2A/D-mediated auto-
inhibition of neurotransmitter release is already present immedi-
ately after birth (27). Activation of the a2A/D and a2C receptors in the
sympathetic nerve terminals by dexmedetomidine inhibits
voltage-dependent Ca2þ channels and resulting norepinephrine
release (28). In support of this, pharmacological block of N-type
Ca2þ channels, which play a major role in the sympathetic nerve
terminals (29), were shown to inhibit the EFS-induced increase in
LVP (24), similar to the present result (Fig. 6).
In contrast, the effect of dexmedetomidine on CPP differed
depending on postnatal age, i.e., dexmedetomidine did not affect
CPP in young hearts (<4 weeks) but increased CPP by 10e15 mmHg
in older hearts. The dexmedetomidine-induced elevation of CPP
was suppressed by imiloxan, indicating that this was mediated by
a2B receptors. The inhibitory effect of imiloxan was attenuated by
increasing the dexmedetomidine concentration from 10 to 100 nM.
This suggests that there was competitive antagonism between
dexmedetomidine and imiloxan at the a2B receptor. Essentially
similar effects were observed for prazosin. Although prazosin is
known as an a1 receptor antagonist (Ki < 1 nM), a radioligand
binding study showed that Ki values were signiﬁcantly lower
(30 nM) for a2B receptors than for a2A receptors (Ki ¼ 1000 nM)
(30). It was also reported that the Ki values for imiloxan were
1750 nM and 50 nM for a2A receptors and a2B receptors, respec-
tively (30). Thus prazosin appears to be more speciﬁc and effective
in inhibiting a2B receptors than imiloxan.
As adrenoceptor activation of vascular postsynaptic receptors
can cause both vasoconstriction and vasodilation, the overall effects
of a2 receptor activation are complex, andmay differ among variousvascular preparations. It has been reported that multiple a2 re-
ceptors can cause vasoconstriction in most vascular beds (31). In
general, a2A receptors are expressed exclusively in large arteries,
whereas a2B receptors contribute more to vascular tone in small
arteries and veins (31). Nonselective activation of a2 receptors
usually leads to a biphasic blood pressure response: a short hy-
pertensive phase that is induced by a2B receptors followed by long-
lasting hypotensionmediated by a2A receptors (32). In the coronary
circulation, a1 and a2 adrenoceptors contribute to coronary vaso-
constriction. While a1 receptors induce vasoconstriction of epicar-
dial conduit vessels and participate in microvascular
vasoconstriction of resistive vessels, a2 receptors predominantly
mediate microvascular resistive vessel constriction (33), although
the speciﬁc receptor subtypes mediating this constriction have not
been deﬁned. It has been reported that intracoronary infusion of
the selective a2 agonist xylometazoline increased coronary resis-
tance by a maximum of 60% (33). When assessed with 15O-labeled
water and positron emission tomography in healthy male subjects,
coronary vascular resistance increased in response to dexmedeto-
midine infusion (34). Coronary artery resistance also increased
with dexmedetomidine at doses of 1 mg/kg or higher in anes-
thetized goats (35). All these ﬁndings, together with the present
results that dexmedetomidine-induced elevation of CPP was sup-
pressed by imiloxan, support the view that dexmedetomidine-
induced elevation of CPP probably results from activation of a2B
receptors. The lack of effects of clonidine, a non-selective a2 agonist,
on CPP is also consistent with this view, since dexmedetomidine
was approximately 10 times more potent for a2 receptors than
clonidine (36).
The reason why dexmedetomidine did not increase CPP in
young guinea pig hearts is not known at present. We speculate that
the expression of a2 receptor subtypes may change during the
course of development. An alteration in a-adrenergic receptor-
mediated effects has been reported in various organs and tissues.
For example, ontogenetic proﬁles differed substantially between
two a adrenergic receptor types in rat hearts, i.e., a1 receptors
showed a striking increment during the ﬁrst 2 weeks postpartum,
while a2 receptors declined markedly during the ﬁrst week and
remained low thereafter (37). In cerebellar Purkinje cells, inhibitory
effects of a₂ receptors are absent until the second postnatal week,
and became predominant thereafter (38). Further studies including
the immunohistochemistry and the measurement of mRNA level or
protein levels of adrenoceptor subtypes in cardiac ventricles and
M. Hongo et al. / Journal of Pharmacological Sciences 131 (2016) 118e125124coronary artery in different ages are necessary to elucidate the
mechanisms of age-dependent effects of dexmedetomidine on
coronary resistance. Also, it is important to know whether
dexmedetomidine-induced elevation of CPP was observed in
knock-out mice with deletion of the a2B adrenoceptor.
The response of CPP to EFS was characterized by a biphasic
change in CPP, i.e., a transient increase was followed by sustained
decrease (Fig. 5). The transient increase is probably due to a2B re-
ceptor activation, and the sustained decrease might be derived
from b receptor activation. It has been also known that locally
produced vasoactive hormones (i.e. adenosine, bradykinin) are
capable of inducing vasorelaxation of coronary resistance arteries
via the endothelium. Thus, it is also possible that the increased
contractility in response to EFS facilitated the production of these
vasoactive hormones, thereby causing the sustained decrease of
CPP. In any cases, dexmedetomidine attenuated both responses via
the suppression of norepinephrine release from the sympathetic
nerve terminals.
Dexmedetomidine is approved by the Food and Drug Adminis-
tration (FDA) for sedation of mechanically ventilated patients at a
dose of 1 mg/kg administered over 10 min followed by infusion of
0.2e0.7 mg/kg/h. The concentration of dexmedetomidinemay reach
10 nM after an initial bolus of 6 mg/kg/h for 10 min, which is rec-
ommended by the FDA. The present study demonstrated that
dexmedetomidine at >10 nM increased CPP and almost completely
inhibited sympathetic stimulation. Therefore, more cautious
administration of dexmedetomidine may be warranted in patients
with parasympathetic dominance in cases where drugs that stim-
ulate parasympathetic nerves, such as certain anesthetic agents, are
used (7,39). Also, a combination of dexmedetomidine with other
cardiodepressant drugs, high sympathetic stimulation, or subclin-
ical coronary artery disease and endothelial dysfunction, could
augment the adverse effects of dexmedetomidine. In addition, the
present study suggests that the increase in coronary vascular
resistance may be another factor related to the adverse effects of
dexmedetomidine, particularly in adults. It has been reported that a
variation in the a2B adrenoreceptor gene was associated with an
increased risk of fatal acute myocardial infarction and sudden car-
diac death, possibly mediated by coronary vasospasm (40). It is
possible that, in certain genetically predisposed individuals, stim-
ulation of a2B receptors by dexmedetomidine may lead to increased
coronary vasoconstriction, thereby leading to myocardial ischemia
and myocardial dysfunction.
In conclusion, the present study showed that dexmedetomidine
inhibits the increase in left ventricular pressure induced by sym-
pathetic stimulation. In addition, dexmedetomidine increases CPP
in hearts of guinea pigs aged >4 weeks. The dexmedetomidine-
induced increase in CPP in adult guinea pig hearts appears to be
mediated by a2B receptors.
Conﬂicts of interest
None of the authors have any conﬂicts of interest associated
with this study.
Acknowledgement
This work was supported by Grants-in-Aid from the Ministry of
Education, Culture, Sports, Science, and Technology of Japan to K. O.
[#22500363, #23136501].
References
(1) Gertler R, Brown H, Mitchell D, Silvius E. Dexmedetomidine: a novel sedative-
analgesic agent. BUMC Proc. 2001;14:13e21.(2) Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in
critically ill adult patients: a meta-analysis. Intensive Care Med. 2010;36:
926e939.
(3) Piao G, Wu J. Systematic review/meta-analysis systematic assessment of
dexmedetomidine as an anesthetic agent: a meta-analysis of randomized
controlled trials. Arch Med Sci. 2014;10:19e24.
(4) Giovannitti JAJ, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists:
a review of current clinical applications. Anesth Prog. 2015;62:31e39.
(5) Ingersoll-Weng E, Manecke Jr GR, Thistlethwaite PA. Dexmedetomidine and
cardiac arrest. Anesthesiology. 2004;100:738e739.
(6) Muntazar M, Kumar FC. Cardiac arrest, a preventable yet a possible risk of
dexmedetomidine: fact or ﬁction? Anesthesiology. 2004;101:1479e1480.
(7) Zhang X, Schmidt U, Wain JC, Bigatello L. Bradycardia leading to asystole
during dexmedetomidine infusion in an 18 year-old double-lung transplant
recipient. J Clin Anesth. 2010;22:45e49.
(8) Sichrovsky TC, Mittal S, Steinberg JS. Dexmedetomidine sedation leading to
refractory cardiogenic shock. Anesth Analg. 2008;106:1784e1786.
(9) Takata K, Adachi YU, Suzuki K, Obata Y, Sato S, Nishiwaki K. Dexmedetomi-
dine-induced atrioventricular block followed by cardiac arrest during atrial
pacing: a case report and review of the literature. J Anesth. 2014;28:116e120.
(10) Lin GY, Robben JH, Murrell JC, Aspegren J, McKusick BC, Hellebrekers LJ.
Dexmedetomidine constant rate infusion for 24 hours during and after pro-
pofol or isoﬂurane anaesthesia in dogs. Vet Anaesth Analg. 2008;35:141e153.
(11) Salmenper€a MT, Szlam F, Hug Jr CC. Anesthetic and hemodynamic interactions
of dexmedetomidine and fentanyl in dogs. Anesthesiology. 1994;80:837e846.
(12) Pascoe PJ. The cardiopulmonary effects of dexmedetomidine infusions in dogs
during isoﬂurane anesthesia. Vet Anaesth Analg. 2015;42:360e368.
(13) Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur J
Pharmacol. 1998;361:1e15.
(14) Gyires K, Zadori ZS, T€or€ok T, Matyus P. a2-Adrenoceptor subtypes-mediated
physiological, pharmacological actions. Neurochem Int. 2009;55:447e453.
(15) Yabuki A, Higuchi H, Yoshitomi T, Tomoyasu Y, Ishii-Maruhama M,
Maeda SMT. Locally injected dexmedetomidine induces vasoconstriction via
peripheral a-2A adrenoceptor subtype in guinea pigs. Reg Anesth Pain Med.
2014;39:133e136.
(16) Friesen RH, Nichols CS, Twite MD, Cardwell KA, Pan Z, Pietra B, et al. The
hemodynamic response to dexmedetomidine loading dose in children with
and without pulmonary hypertension. Anesth Analg. 2013;117:953e959.
(17) Holliday SF, Kane-Gill SL, Empey PE, Buckley MS, Smithburger PL. Interpatient
variability in dexmedetomidine response: a survey of the literature. Sci J.
2014;2014:805013.
(18) Kohli U, Diedrich A, Kannankeril PJ, Muszkat M, Sofowora GG, Hahn MK, et al.
Genetic variation in alpha2-adrenoreceptors and heart rate recovery after
exercise. Physiol Genomics. 2015;47:400e406.
(19) Chen B-S, Peng H, Wu S-N. Dexmedetomidine, an alpha2-adrenergic agonist,
inhibits neuronal delayed-rectiﬁer potassium current and sodium current. Br J
Anaesth. 2009;103:244e254.
(20) Kawano T, Yamazaki F, Chi H, Kawahito S, Eguchi S. Dexmedetomidine
directly inhibits vascular ATP-sensitive potassium channels. Life Sci. 2012;90:
272e277.
(21) Yang Y, Meng Q, Pan X, Xia Z, Chen X. Dexmedetomidine produced analgesic
effect via inhibition of HCN currents. Eur J Pharmacol. 2014;740:560e564.
(22) Shirasaka T, Ph D, Kannan H, Takasaki M. Activation of a G Protein e coupled
inwardly rectifying Kþ current and suppression of Ih contribute to
dexmedetomidine-induced inhibition of rat hypothalamic paraventricular
nucleus neurons. Anesthesiology. 2007;107:605e615.
(23) Shibata S, Okamoto Y, Endo S, Ono K. Direct effects of esmolol and landiolol on
cardiac function, coronary vasoactivity, and ventricular electrophysiology in
Guinea-Pig hearts. J Pharmacol Sci. 2012;118:255e265.
(24) Murakami M, Ohba T, Xu F, Satoh E, Miyoshi I, Suzuki T, et al. Modiﬁed
sympathetic nerve system activity with overexpression of the voltage-
dependent calcium channel beta3 subunit. J Biol Chem. 2008;283:
24554e24560.
(25) Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M. Alpha2-
adrenoceptor agonists stimulate high-afﬁnity GTPase activity in a receptor
subtype-selective manner. Eur J Pharmacol. 1999;374:137e146.
(26) Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic
receptors regulate sympathetic neurotransmission. Nature. 1999;402:
181e184.
(27) Schelb V, G€obel I, Khairallah L, Zhou H, Cox SL, Trendelenburg AU, et al.
Postnatal development of presynaptic receptors that modulate noradrenaline
release in mice. Naunyn Schmiedeb Arch Pharmacol. 2001;364:359e371.
(28) Trendelenburg AU, Cox SL, Gaiser EG, Meyer A, Starke K. Noradrenaline
release from cultured mouse postganglionic sympathetic neurons:
autoreceptor-mediated modulation. J Neurochem. 1999;73:1439e1445.
(29) Molderings GJ, Likungu J, Gothert M. N-Type calcium channels control sym-
pathetic neurotransmission in human heart atrium. Circulation. 2000;101:
403e407.
(30) Bylund D. International union of pharmacology nomenclature of adreno-
ceptor. Pharmacol Rev. 1994;46:121e136.
(31) Kanagy NL. a2 -Adrenergic receptor signalling in hypertension. Clin Sci.
2005;437:431e437.
(32) Philipp M, Brede M, Hein L, Physiological LH. Physiological signiﬁcance of
alpha2-adrenergic receptor subtype diversity: one receptor is not enough. Am
J Physiol e Regul Integr Comp Physiol. 2002;283:287e295.
M. Hongo et al. / Journal of Pharmacological Sciences 131 (2016) 118e125 125(33) Heusch G. The paradox of a-adrenergic coronary vasoconstriction revisited.
J Mol Cell Cardiol. 2011;51:16e23.
(34) Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, et al. Effects of
low and high plasma concentrations of dexmedetomidine on myocardial
perfusion and cardiac function in healthy male subjects. Anesthesiology.
2006;105:902e910.
(35) Lawrence CJ, Prinzen FW, de Lange S. Hemodynamic and coronary vascular
effects of dexmedetomidine in the anesthetized goat. Acta Anaesthesiol
Scand. 1997;41:830e836.
(36) Olli-L€ahdesm€aki T, Tiger M, Vainio M, Scheinin M, Kallio J. Ligand-induced a2-
adrenoceptor endocytosis: relationship to Gi protein activation. Biochem
Biophys Res Commun. 2004;321:226e233.(37) Metz LD, Seidler FJ, McCook EC, Slotkin TA. Cardiac alpha-adrenergic receptor
expression is regulated by thyroid hormone during a critical developmental
period. J Mol Cell Cardiol. 1996;28:1033e1044.
(38) Hirono M, Nagao S, Obata K. Developmental a2-adrenergic regulation of
noradrenergic synaptic facilitation at cerebellar GABAergic synapses. Neuro-
science. 2014;256:242e251.
(39) Schlichter RA. Dexmedetomidine is an excellent agent for sedation status-post
lung transplant. J Clin Anesth. 2010;22:1e2.
(40) Snapir A,Mikkelsson J, PerolaM, Penttil€aA, ScheininM,KarhunenPJ. Variation in
the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial
infarction and sudden cardiac death. J Am Coll Cardiol. 2003;41:190e194.
